Amylyx Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	49.27	-198.38	-87.93	-42.28	-13.72
Depreciation & Amortization	1.09	0.49	0.05	0	0
Share-Based Compensation	37.16	21.71	3.14	0.24	0.11
Other Operating Activities	-75.6	-3.7	9.94	5.34	2.92
Operating Cash Flow	11.92	-179.87	-74.8	-36.7	-10.69
Capital Expenditures	-1.24	-2.53	-0.35	-0.15	0
Change in Investments	93.29	-236.46	-46.05	0	0
Investing Cash Flow	92.05	-238.99	-46.41	-0.15	0
Share Issuance / Repurchase	6.99	434.64	0.34	0.05	0.03
Debt Issued / Paid	0	0	25.85	16.82	0.64
Other Financing Activities	-3.45	-2.85	132.32	29.96	-
Financing Cash Flow	3.54	431.79	158.51	46.82	0.67
Exchange Rate Effect	0.16	-0.07	0.01	0	0
Net Cash Flow	107.68	12.87	37.31	9.98	-10.02
Free Cash Flow	10.68	-182.4	-75.15	-36.85	-10.69
Free Cash Flow Margin	2.80%	-820.50%	-26369.12%	-5668.92%	-749.44%
Free Cash Flow Per Share	0.16	-3.12	-11.41	-6.06	-1.81

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).